Avai Bio (AVAI) Liabilities and Shareholders Equity (2018 - 2025)

Avai Bio has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $172912.0 for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $172912.0, down 1.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $774335.0 (down 16.09% YoY), and the FY2025 annual result was $224745.0, down 30.21% from the prior year.
• Liabilities and Shareholders Equity came in at $172912.0 for Q4 2025 at Avai Bio, down from $231372.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $871981.0 in Q2 2021 to a low of $145306.0 in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $279654.5 (2022), against an average of $352475.4.
• Across the five-year window, Liabilities and Shareholders Equity surged 94.36% in 2021 and tumbled 55.41% in 2022, its largest moves.
• Avai Bio's Liabilities and Shareholders Equity stood at $427091.0 in 2021, then tumbled by 33.3% to $284890.0 in 2022, then grew by 2.23% to $291246.0 in 2023, then sank by 39.95% to $174886.0 in 2024, then retreated by 1.13% to $172912.0 in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $172912.0 (Q4 2025), $231372.0 (Q3 2025), and $145306.0 (Q2 2025), per Business Quant data.